Assessing GitLab (GTLB) Valuation As Anthropic Claude Integration Deepens Its Secure AI Development Platform

GitLab (GTLB) is back in the spotlight after announcing deeper integration of Anthropic’s Claude models into its GitLab Duo Agent Platform, tying advanced AI assistants directly into its existing governance and compliance framework.

See our latest analysis for GitLab.

These AI partnerships arrive after a mixed year for GitLab’s stock, with a 7 day share price return of 7.16% contrasted against a 90 day share price return decline of 36.71% and a 1 year total shareholder return decline of 52.85%. This suggests recent optimism following a sharp reset in expectations.

If this kind of AI driven story has your attention, it may be worth broadening your search using our screener of 33 AI small caps

So with GitLab’s shares down sharply over the past year, but now seeing renewed interest around its AI platform, are you looking at an undervalued DevSecOps player or a stock where future growth is already priced in?

Advertisement

Most Popular Narrative: 85.2% Undervalued

GitLab’s last close at $22.14 sits far below the $150 fair value implied by the most followed narrative, which frames the stock as heavily discounted.

But where does "GTLB" come into play? Open-source technology is growing at a fast, sophisticated level that the Major 7 can't keep up with. As Microsoft, Tesla, and Nvidia all crash from cyber-attacks and bots draining free cash flow, the Major 7 made a mistake and allowed open-source technology to slowly start to take over these bearish markets, allowing GitLab to make a stand with their "DevSecOps" system security.

Read the complete narrative.

According to TeamDaily, this fair value leans heavily on ambitious revenue growth, rising margins and a future earnings multiple more often associated with mature software leaders.

Result: Fair Value of $150 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this bullish story could be challenged if GitLab’s revenue growth of 12.47% slows further, or if ongoing net losses of US$55.956 million persist.

Find out about the key risks to this GitLab narrative.

Next Steps

Given the mix of enthusiasm and caution in this story, it makes sense to check the numbers yourself and decide where you stand. To weigh both sides quickly, start with the 2 key rewards and 3 important warning signs.

Looking for more investment ideas?

If GitLab has sharpened your interest, do not stop here. Use curated stock lists to spot other opportunities that could fit your portfolio before others do.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqGS:GTLB

GitLab

Develops software for the software development lifecycle in the United States, Europe, and the Asia Pacific.

Flawless balance sheet and good value.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1155.3% undervalued
51 users have followed this narrative
2 users have commented on this narrative
9 users have liked this narrative
BL
BlackGoat
IREN logo
BlackGoat on IREN ·

IREN's Bold Moves in Sustainable Bitcoin Mining & AI Data Centers

Fair Value:US$71.4849.2% undervalued
204 users have followed this narrative
6 users have commented on this narrative
32 users have liked this narrative
HE
HedgeY
ARM logo
HedgeY on Arm Holdings ·

The Architecture Layer of AI Computing - But Priced Like the Future Already Arrived?

Fair Value:US$43038.1% undervalued
9 users have followed this narrative
1 users have commented on this narrative
3 users have liked this narrative
HI
Hidden_Rock_Capital
FISV logo
Hidden_Rock_Capital on Fiserv ·

Temporary "perfect storm" leads to opportunity to buy financial services leader for less than 5x long-term earnings

Fair Value:US$119.9956.4% undervalued
13 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative

Updated Narratives

EU
European_Hidden_Gem_Stocks
ALMIN logo
European_Hidden_Gem_Stocks on MINT Société anonyme ·

Mint SA: A French Micro-Cap Energy Retailer Worth Watching

Fair Value:€1153.1% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
KA
kaspertidemann
BARDJU logo
kaspertidemann on BAR DJUS ·

The Best Season Is Still Ahead

Fair Value:DKK 4.120.5% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
CL
Clive_Thompson
6831 logo
Clive_Thompson on Green Tea Group ·

One of China's Fastest-Growing Restaurant Chains Trades on Just 7x Earnings and an 8% Dividend

Fair Value:HK$8.728.9% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.917.3% undervalued
86 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28029.8% undervalued
195 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.7% undervalued
72 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0
BE
Ben_Dur
FMG logo
Ben_Dur on Fortescue ·

test

0
|
0